An extension trial comparing safety and efficacy of NN5401 plus meal-time insulin aspart for the remaining meals with insulin detemir plus meal-time insulin aspart in type 1 diabetes The primary objective is to investigate the long-term safety and tolerability of SIAC. This is done by comparing SIAC to insulin detemir after 52 weeks of treatment (26 weeks of treatment in trial NN5...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A single-centre, randomised, double-blind, cross-over trial comparing the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents with type 1 diabetes • To compare the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents (6 to 17 years) with type 1 diabetes

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) Subjects with Type 2 Diabetes To assess the safety and tolerability of 0.3, 0.6, 0.9, 1.2 and 1.8 mg doses of liraglutide in the paediatric population (10 – 17 years of age).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A To evaluate immunogenicity of NNC 0129-0000-1003 (hereafter referred to as N8-GP)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of prophylactic administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients with Inhibitors The primary objective is to determine the safety including the potential immunogenicity of LArFVIIa intravenously administered to haemophilia patients with inhibitors every second day for 12 weeks at ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2 To evaluate the safety of five escalating doses of NN1731 in haemophilia subjects with inhibitors being treated for acute joint bleeds.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Comparing semaglutide once a week to liraglutide once a day as add-on to 1-3 anti-diabetes tablets (OADs) in people with type 2 diabetes To compare the effect of semaglutide subcutaneous (s.c.) 1.0 mg once-weekly versus liraglutide s.c. 1.2 mg once-daily on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The efficacy of insulin degludec/liraglutide as add-on therapy in controlling glycaemia in adults with type 2 diabetes inadequately controlled on sulphonylurea with or without metformin therapy To confirm superiority of insulin degludec/liraglutide compared to insulin degludec/liraglutide placebo in controlling glycaemia as add-on treatment in insulin naïve subjects with Type 2 Diabetes Mell...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in pre-pubertal children with growth hormone deficiency previously untreated with growth hormone To evaluate the efficacy of multiple dose regimens of once-weekly NNC0195-0092 after 26 weeks of treatment in GH treatment naïve pre-pubertal children with GHD compared to once-daily hGH administratio...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomised, open-label, multi-centre trial investigating the intra-subject variability of ROTEM® and TEG® parameters following two intravenous administrations of the same dose of activated recombinant factor VII (rFVIIa/NovoSeven®) in haemophilia patients in a non-bleeding state • To evaluate the intra-subject variability (in vivo reproducibility) of thromboelastographic parameters as measured by ROTEM® and by TEG® prior to and at 15, 60, 120 and 240 minutes following two adm...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune